Screener
Exelixis EXEL Collaboration — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Exelixis’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q3 2026
- Accession
- 0000939767-26-000098
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Net product revenues | $573,025 | $520,014 | $1,128,002 | $1,033,297 |
| Collaboration revenues | 55,665 | 48,247 | 111,500 | 90,411 |
| Total revenues | 628,690 | 568,261 | 1,239,502 | 1,123,708 |
| Operating expenses: | ||||
| Cost of goods sold | 20,657 | 19,470 | 40,610 | 38,642 |
| Research and development | 211,987 | 200,356 | 411,903 | 412,589 |
| Selling, general and administrative | 147,632 | 134,859 | 287,234 | 272,042 |
Item 1. Financial Statements.
FAQ
- What is Exelixis's collaboration — total revenues?
- Exelixis (EXEL) reported collaboration — total revenues of $55.67M in Q2 2026.
- How has Exelixis's collaboration — total revenues changed year-over-year?
- Exelixis's collaboration — total revenues increased by 15.4% year-over-year, from $48.25M to $55.67M.
- What is the long-term trend for Exelixis's collaboration — total revenues?
- Over 4 years (2021 to 2025), Exelixis's collaboration — total revenues has grown at a -13.8% compound annual growth rate (CAGR), from $357.71M to $197.32M.
- What does collaboration — total revenues mean?
- This metric represents the total revenue generated through strategic partnerships, licensing agreements, and collaborative research and development efforts with other biopharmaceutical entities. It captures income streams derived from milestone payments, royalties, and shared profit arrangements related to the commercialization of jointly developed therapeutic assets. This revenue segment reflects the company's ability to leverage external expertise and distribution networks to monetize its drug discovery pipeline.
Ask your AI about Exelixis's collaboration — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude